Compare T Rowe Price Group Inc (TROW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Viatris Inc — how do they compare? T Rowe Price Group Inc trades at $104.25 (market cap $22.23B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: T Rowe Price Group Inc and Viatris Inc are close in size by market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold T Rowe Price Group Inc for 115 Days and Viatris Inc for 57 Days on average.
| TROW | VTRS | |
|---|---|---|
Market Cap | $22.23B | $20.03B |
Volume | 2,834,949 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $121.68 | $18.27 |
52-Week Low | $86.19 | $9.74 |
Typical Hold Time | 115 Days | 57 Days |
Enterprise Value | $19.43B | $32.15B |
Dividend Yield | 4.99% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price Group (TROW) trades at $104.07, up 0.45% with bearish technical signals but strong fundamentals including a 10.45 P/E ratio and 29.26% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 slightly missed. The company maintains robust cash flow with $704.4M net cash flow in 2025 and a dividend yield near 5% with 40 years of consecutive growth.
The stock offers value with attractive valuation metrics and consistent profitability, though technical indicators suggest near-term pressure. Key risks include market-sensitive revenue streams and net outflows, while analyst consensus at $112 target implies 7.6% upside potential from current levels.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
